These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11500516)

  • 61. Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis.
    Boerner JL; Danielsen AJ; Lovejoy CA; Wang Z; Juneja SC; Faupel-Badger JM; Darce JR; Maihle NJ
    Oncogene; 2003 Oct; 22(43):6679-89. PubMed ID: 14555981
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform.
    Cha JY; Maddileti S; Mitin N; Harden TK; Der CJ
    J Biol Chem; 2009 Mar; 284(10):6227-40. PubMed ID: 19103595
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Identification of the binding site for the Shc protein to the avian erythroblastosis virus (AEV-H) v-erbB protein.
    Labudda K; Meyer S; Hayman MJ
    Virology; 1995 Jan; 206(1):269-75. PubMed ID: 7831781
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The SH2 inositol 5-phosphatase Ship1 is recruited in an SH2-dependent manner to the erythropoietin receptor.
    Mason JM; Beattie BK; Liu Q; Dumont DJ; Barber DL
    J Biol Chem; 2000 Feb; 275(6):4398-406. PubMed ID: 10660611
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tyrosine 474 of ZAP-70 is required for association with the Shc adaptor and for T-cell antigen receptor-dependent gene activation.
    Pacini S; Ulivieri C; Di Somma MM; Isacchi A; Lanfrancone L; Pelicci PG; Telford JL; Baldari CT
    J Biol Chem; 1998 Aug; 273(32):20487-93. PubMed ID: 9685404
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Val(659)-->Glu mutation within the transmembrane domain of ErbB-2: effects measured by (2)H NMR in fluid phospholipid bilayers.
    Sharpe S; Barber KR; Grant CW
    Biochemistry; 2000 May; 39(21):6572-80. PubMed ID: 10828974
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation.
    Lannon CL; Martin MJ; Tognon CE; Jin W; Kim SJ; Sorensen PH
    J Biol Chem; 2004 Feb; 279(8):6225-34. PubMed ID: 14668342
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Impaired Shc, Ras, and MAPK activation but normal Akt activation in FL5.12 cells expressing an insulin-like growth factor I receptor mutated at tyrosines 1250 and 1251.
    Leahy M; Lyons A; Krause D; O'Connor R
    J Biol Chem; 2004 Apr; 279(18):18306-13. PubMed ID: 14963047
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation.
    Qian X; Dougall WC; Fei Z; Greene MI
    Oncogene; 1995 Jan; 10(1):211-9. PubMed ID: 7824275
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tyrosine phosphorylation of the beta 4 integrin cytoplasmic domain mediates Shc signaling to extracellular signal-regulated kinase and antagonizes formation of hemidesmosomes.
    Dans M; Gagnoux-Palacios L; Blaikie P; Klein S; Mariotti A; Giancotti FG
    J Biol Chem; 2001 Jan; 276(2):1494-502. PubMed ID: 11044453
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dok-1 tyrosine residues at 336 and 340 are essential for the negative regulation of Ras-Erk signalling, but dispensable for rasGAP-binding.
    Shinohara H; Yasuda T; Yamanashi Y
    Genes Cells; 2004 Jun; 9(6):601-7. PubMed ID: 15189452
    [TBL] [Abstract][Full Text] [Related]  

  • 72. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer.
    Lai GH; Zhang Z; Shen XN; Ward DJ; Dewitt JL; Holt SE; Rozich RA; Hixson DC; Sirica AE
    Gastroenterology; 2005 Dec; 129(6):2047-57. PubMed ID: 16344070
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Focal adhesion kinase overexpression enhances ras-dependent integrin signaling to ERK2/mitogen-activated protein kinase through interactions with and activation of c-Src.
    Schlaepfer DD; Hunter T
    J Biol Chem; 1997 May; 272(20):13189-95. PubMed ID: 9148935
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth.
    Chuang TD; Chen SJ; Lin FF; Veeramani S; Kumar S; Batra SK; Tu Y; Lin MF
    J Biol Chem; 2010 Jul; 285(31):23598-606. PubMed ID: 20498373
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Modulation of erbB kinase activity and oncogenic potential by single point mutations in the glycine loop of the catalytic domain.
    Shu HK; Chang CM; Ravi L; Ling L; Castellano CM; Walter E; Pelley RJ; Kung HJ
    Mol Cell Biol; 1994 Oct; 14(10):6868-78. PubMed ID: 7935404
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Identification of a novel conserved signaling motif in CD200 receptor required for its inhibitory function.
    Timmerman LM; de Graaf JF; Satravelas N; Kesmir Ç; Meyaard L; van der Vlist M
    PLoS One; 2021; 16(3):e0244770. PubMed ID: 33780466
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Expanding the Disorder-Function Paradigm in the C-Terminal Tails of Erbbs.
    Pinet L; Assrir N; van Heijenoort C
    Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827688
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Structural and dynamic characterization of the C-terminal tail of ErbB2: Disordered but not random.
    Pinet L; Wang YH; Deville C; Lescop E; Guerlesquin F; Badache A; Bontems F; Morellet N; Durand D; Assrir N; van Heijenoort C
    Biophys J; 2021 May; 120(10):1869-1882. PubMed ID: 33741354
    [TBL] [Abstract][Full Text] [Related]  

  • 79. SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane.
    Li H; Zhang M; Wei Y; Haider F; Lin Y; Guan W; Liu Y; Zhang S; Yuan R; Yang X; Yang S; Wang H
    J Exp Clin Cancer Res; 2020 May; 39(1):81. PubMed ID: 32381043
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems.
    Nagaria TS; Shi C; Leduc C; Hoskin V; Sikdar S; Sangrar W; Greer PA
    Oncotarget; 2017 Oct; 8(46):80804-80819. PubMed ID: 29113345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.